Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Centre, Double-Blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura

Next Previous
X
Search
Trial Profile

A Single Centre, Double-Blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tonabersat (Primary)
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Minster Pharmaceuticals

    • Most Recent Events

    • 10 Sep 2009 Results have been reported at the 14th International Headache Congress & the 51st Annual Scientific Meeting of the American Headache Society (Joint meeting; AHS/IHS 2009).
    • 01 Sep 2009 Actual number of patients changed from 31 to 39 as reported by ClinicalTrials.gov.
    • 24 Oct 2008 Status changed from recruiting to completed as reported in a Minster Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top